Know your quantitative antibody levels to determine how you responded to the vaccine.

About Allermetrix

Allermetrix is the leading expert in the field of antibody testing. Allermetrix was founded over 15 years ago by two Phd's that have devoted their life work to studying the body's immune response. Allermetrix is headquartered in Nashville, Tennessee. Allermetrix is a College of American Pathology (CAP) certified allergy and immunology specialty laboratory that is entirely owned by two scientists who have devoted their careers to the field of antibody testing.

About the Founders

Jay Weiss, Ph.D.
Northwestern University, Tumor Cell Biology

Dr. Weiss has been actively involved in antibody test development and clinical trials for over 40 years focusing on the field of allergy. He is currently President of Allermetrix, which he cofounded in 2006. He has designed and directed test development programs for various antibodies including: Total IgE, specific IgE, specific IgG and specific IgG4.

Dr. Weiss has served as the President of the In Vitro Allergy Diagnostic Manufacturers Association, and advisor to the NCCLS In Vitro Specific IgE Standardization Committee. He is currently on the board of directors for the American Association of Bioanalysts (AAB). He has published several articles related to latex allergy and given numerous lectures on diagnostic allergy antibody testing throughout the world. Recently he presented a webinar on COVID-19 antibody testing sponsored by the AAB. Dr Weiss directs research and development at Allermetrix and is currently focused on COVID-19 antibody testing.

Gary Kitos, Ph.D., H.C.L.D., C.C.
Syracuse University, Biophysics

Dr. Kitos' clinical immunology career began in an FDA approved allergy extract pharmaceutical company. He has developed specific IgE and specific IgG4 antibody tests and integrated these tests into the reference laboratory environment. His unique background in allergy extracts and formulation coupled with his clinical immunology background has formed the basis for his test strategy approaches in the field of allergy and immunology. Over the years he has designed and developed several allergy laboratory information systems (LIS) and was the first to offer interpretative allergy patient reports. Dr. Kitos is the Medical Laboratory Director and is board certified as a High Complexity Laboratory Director and Clinical Consultant by the ABB.

How Allermetrix Developed a Unique, Quantitative COVID-19 Antibody Test

Allermetrix is a High Complexity Laboratory that developed a proprietary, antibody testing assay over 15 years ago. Currently we can test over 500 allergens with three different antibody types (IgG, IgE and IgG4) quantitatively. Over the years we have continually improved our technology. When the COVID-19 virus arrived, we immediately recognized the need to identify antibodies related to the virus. Most important was to identify the major markers of the virus. From the initial studies it became obvious that antibodies to the RBD (receptor binding domain) the S1-protein (a subunit of the spike protein) and the N-protein (nucleocapsid protein) would need to be followed. After obtaining the materials, an antibody test was developed utilizing our existing liquid allergen technology by mid July 2020. Currently, Allermetrix is the only laboratory offering a quantitative COVID-19 antibody test.